PortalPublikationenUp- and downgrading in single intermediate-risk positive bio...

Up- and downgrading in single intermediate-risk positive biopsy core prostate cancer

Standard

Up- and downgrading in single intermediate-risk positive biopsy core prostate cancer. / Hoeh, Benedikt; Flammia, Rocco; Hohenhorst, Lukas; Sorce, Gabriele; Chierigo, Francesco; Tian, Zhe; Saad, Fred; Gallucci, Michele; Briganti, Alberto; Terrone, Carlo; Shariat, Shahrokh F; Graefen, Markus; Tilki, Derya; Kluth, Luis A; Mandel, Philipp; Chun, Felix K H; Karakiewicz, Pierre I.

in: PROSTATE INT, Jahrgang 10, Nr. 1, 03.2022, S. 21-27.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Hoeh, B, Flammia, R, Hohenhorst, L, Sorce, G, Chierigo, F, Tian, Z, Saad, F, Gallucci, M, Briganti, A, Terrone, C, Shariat, SF, Graefen, M, Tilki, D, Kluth, LA, Mandel, P, Chun, FKH & Karakiewicz, PI 2022, 'Up- and downgrading in single intermediate-risk positive biopsy core prostate cancer', PROSTATE INT, Jg. 10, Nr. 1, S. 21-27. https://doi.org/10.1016/j.prnil.2022.01.004

APA

Hoeh, B., Flammia, R., Hohenhorst, L., Sorce, G., Chierigo, F., Tian, Z., Saad, F., Gallucci, M., Briganti, A., Terrone, C., Shariat, S. F., Graefen, M., Tilki, D., Kluth, L. A., Mandel, P., Chun, F. K. H., & Karakiewicz, P. I. (2022). Up- and downgrading in single intermediate-risk positive biopsy core prostate cancer. PROSTATE INT, 10(1), 21-27. https://doi.org/10.1016/j.prnil.2022.01.004

Vancouver

Hoeh B, Flammia R, Hohenhorst L, Sorce G, Chierigo F, Tian Z et al. Up- and downgrading in single intermediate-risk positive biopsy core prostate cancer. PROSTATE INT. 2022 Mär;10(1):21-27. https://doi.org/10.1016/j.prnil.2022.01.004

Bibtex

@article{4ab51944c70d41fb8fcdebff732120c2,
title = "Up- and downgrading in single intermediate-risk positive biopsy core prostate cancer",
abstract = "BACKGROUND: Up- and/or downgrading rates in single intermediate-risk positive biopsy core are unknown.METHODS: We identified single intermediate-risk (Gleason grade group (GGG) 2/GGG3) positive biopsy core prostate cancer patients (≤ cT2c and PSA ≤ 20 ng/mL) within the Surveillance, Epidemiology, and End Results (SEER) database (2010-2015). Subsequently, separate uni- and multivariable logistic regression models tested for independent predictors of up- and downgrading.RESULTS: Of 1,328 assessable patients with single core positive intermediate-risk prostate cancer at biopsy, 972 (73%) harbored GGG2 versus 356 (27%) harbored GGG3. Median PSA (5.5 vs 5.7; p = 0.3), median age (62 vs 63 years; p = 0.07) and cT1-stage (77 vs 75%; p = 0.3) did not differ between GGG2 and GGG3 patients. Of individuals with single GGG2 positive biopsy core, 191 (20%) showed downgrading to GGG1 versus 35 (4%) upgrading to GGG4 or GGG5 at RP. Of individuals with single GGG3 positive biopsy core, 36 (10%) showed downgrading to GGG1 versus 42 (12%) significant upgrading to GGG4 or GGG5 at RP. In multivariable logistic regression models, elevated PSA (10-20 ng/mL) was an independent predictor of upgrading to GGG4/GGG5 in single GGG3 positive biopsy core patients (OR:2.89; 95%-CI: 1.31-6.11; p = 0.007).CONCLUSION: In single GGG2 positive biopsy core patients, downgrading was four times more often recorded compared to upgrading. Conversely, in single GGG3 positive biopsy core patients, up- and downgrading rates were comparable and should be expected in one out of ten patients.",
author = "Benedikt Hoeh and Rocco Flammia and Lukas Hohenhorst and Gabriele Sorce and Francesco Chierigo and Zhe Tian and Fred Saad and Michele Gallucci and Alberto Briganti and Carlo Terrone and Shariat, {Shahrokh F} and Markus Graefen and Derya Tilki and Kluth, {Luis A} and Philipp Mandel and Chun, {Felix K H} and Karakiewicz, {Pierre I}",
note = "{\textcopyright} 2022 Asian Pacific Prostate Society. Published by Elsevier B.V.",
year = "2022",
month = mar,
doi = "10.1016/j.prnil.2022.01.004",
language = "English",
volume = "10",
pages = "21--27",
journal = "PROSTATE INT",
issn = "2287-8882",
publisher = "Elsevier Inc.",
number = "1",

}

RIS

TY - JOUR

T1 - Up- and downgrading in single intermediate-risk positive biopsy core prostate cancer

AU - Hoeh, Benedikt

AU - Flammia, Rocco

AU - Hohenhorst, Lukas

AU - Sorce, Gabriele

AU - Chierigo, Francesco

AU - Tian, Zhe

AU - Saad, Fred

AU - Gallucci, Michele

AU - Briganti, Alberto

AU - Terrone, Carlo

AU - Shariat, Shahrokh F

AU - Graefen, Markus

AU - Tilki, Derya

AU - Kluth, Luis A

AU - Mandel, Philipp

AU - Chun, Felix K H

AU - Karakiewicz, Pierre I

N1 - © 2022 Asian Pacific Prostate Society. Published by Elsevier B.V.

PY - 2022/3

Y1 - 2022/3

N2 - BACKGROUND: Up- and/or downgrading rates in single intermediate-risk positive biopsy core are unknown.METHODS: We identified single intermediate-risk (Gleason grade group (GGG) 2/GGG3) positive biopsy core prostate cancer patients (≤ cT2c and PSA ≤ 20 ng/mL) within the Surveillance, Epidemiology, and End Results (SEER) database (2010-2015). Subsequently, separate uni- and multivariable logistic regression models tested for independent predictors of up- and downgrading.RESULTS: Of 1,328 assessable patients with single core positive intermediate-risk prostate cancer at biopsy, 972 (73%) harbored GGG2 versus 356 (27%) harbored GGG3. Median PSA (5.5 vs 5.7; p = 0.3), median age (62 vs 63 years; p = 0.07) and cT1-stage (77 vs 75%; p = 0.3) did not differ between GGG2 and GGG3 patients. Of individuals with single GGG2 positive biopsy core, 191 (20%) showed downgrading to GGG1 versus 35 (4%) upgrading to GGG4 or GGG5 at RP. Of individuals with single GGG3 positive biopsy core, 36 (10%) showed downgrading to GGG1 versus 42 (12%) significant upgrading to GGG4 or GGG5 at RP. In multivariable logistic regression models, elevated PSA (10-20 ng/mL) was an independent predictor of upgrading to GGG4/GGG5 in single GGG3 positive biopsy core patients (OR:2.89; 95%-CI: 1.31-6.11; p = 0.007).CONCLUSION: In single GGG2 positive biopsy core patients, downgrading was four times more often recorded compared to upgrading. Conversely, in single GGG3 positive biopsy core patients, up- and downgrading rates were comparable and should be expected in one out of ten patients.

AB - BACKGROUND: Up- and/or downgrading rates in single intermediate-risk positive biopsy core are unknown.METHODS: We identified single intermediate-risk (Gleason grade group (GGG) 2/GGG3) positive biopsy core prostate cancer patients (≤ cT2c and PSA ≤ 20 ng/mL) within the Surveillance, Epidemiology, and End Results (SEER) database (2010-2015). Subsequently, separate uni- and multivariable logistic regression models tested for independent predictors of up- and downgrading.RESULTS: Of 1,328 assessable patients with single core positive intermediate-risk prostate cancer at biopsy, 972 (73%) harbored GGG2 versus 356 (27%) harbored GGG3. Median PSA (5.5 vs 5.7; p = 0.3), median age (62 vs 63 years; p = 0.07) and cT1-stage (77 vs 75%; p = 0.3) did not differ between GGG2 and GGG3 patients. Of individuals with single GGG2 positive biopsy core, 191 (20%) showed downgrading to GGG1 versus 35 (4%) upgrading to GGG4 or GGG5 at RP. Of individuals with single GGG3 positive biopsy core, 36 (10%) showed downgrading to GGG1 versus 42 (12%) significant upgrading to GGG4 or GGG5 at RP. In multivariable logistic regression models, elevated PSA (10-20 ng/mL) was an independent predictor of upgrading to GGG4/GGG5 in single GGG3 positive biopsy core patients (OR:2.89; 95%-CI: 1.31-6.11; p = 0.007).CONCLUSION: In single GGG2 positive biopsy core patients, downgrading was four times more often recorded compared to upgrading. Conversely, in single GGG3 positive biopsy core patients, up- and downgrading rates were comparable and should be expected in one out of ten patients.

U2 - 10.1016/j.prnil.2022.01.004

DO - 10.1016/j.prnil.2022.01.004

M3 - SCORING: Journal article

C2 - 35261911

VL - 10

SP - 21

EP - 27

JO - PROSTATE INT

JF - PROSTATE INT

SN - 2287-8882

IS - 1

ER -